Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia

Steven R A Simoens
Med J Aust 2011; 194 (1): . || doi: 10.5694/j.1326-5377.2011.tb04156.x
Published online: 3 January 2011

To the Editor: Clarke and Fitzgerald showed that substantial savings could arise from the implementation of alternative pricing arrangements for off-patent statins that provide incentives to reduce prices and increase generic substitution.1 This is exemplified by comparing statin prices between Australia and England. Europe offers some more lessons with respect to savings based on generic medicine usage and how they can be attained.

  • Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, Leuven, Belgium.

  • 1. Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Med J Aust 2010; 192: 633-636. <MJA full text>
  • 2. Simoens S, De Coster S. Potential savings from increased substitution of generic for originator medicines in Europe. J Generic Med 2006; 4: 43-45.
  • 3. Simoens S. International comparison of generic medicine prices. Curr Med Res Opin 2007; 23: 2647-2654.
  • 4. Dylst P, Simoens S. Generic medicine pricing policies in Europe: current status and impact. Pharmaceuticals 2010; 3: 471-481.
  • 5. Dylst P, Simoens S. Does the market share of generic medicines influence the price level? A European analysis. Pharmacoeconomics 2010. In press.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.